In locally advanced dermatofibrosarcoma protuberans (DFSP), imatinib mesylate has been described as an efficient neoadjuvant therapy. This retrospective study included patients with locally advanced DFSP who received neoadjuvant TKI (imatinib or pazopanib) from 2007 to 2017 at Saint Louis Hospital, Paris. The primary endpoint was the evaluation of the long-term status. A total of 27 patients were included, of whom nine had fibrosarcomatous transformation. The median duration of treatment was 7 months. The best response to TKI treatment before surgery, evaluated according to RECIST1.1 on MRI, consisted of complete/partial response (38.5%) or stability (46.2%). DFSP was surgically removed in 24 (89%) patients. A total of 23 patients (85%) were disease-free after 64.8 months of median follow-up (95% confidence interval 47.8; 109.3). One patient developed distant metastases 37 months after surgical tumor resection and finally died. Two patients (7%) did not get surgery because of metastatic progression during TKI treatment, and one patient refused surgery even though the tumor decreased by 30%. Treatment-related adverse events (AE) occurred in 23 patients (85%). Only four patients (imatinib: n = 3, pazopanib: n = 1) had grade ≥3 AE requiring temporary treatment disruption. Neoadjuvant TKI followed by complete surgery with micrographic analysis is an effective strategy for locally advanced and unresectable DFSP, with durable local recurrence disease-free survival.
Objective: Current recommendations for the management of patients with axial spondyloarthritis (axSpA) emphasize the need of an individualized strategy in therapeutic decision-making. The study objectives were to describe therapeutic strategies observed in axSpA, and to assess the factors associated with treatment intensification over time.Methods: We included patients with axSpA from the French prospective cohort DESIR (Devenir des Spondylarthropathies Indifférenciées Récentes), with a scheduled 10-year follow-up. A multistate model with 4 ordered treatment states (no treatment, nonsteroidal antiinflammatory drugs [NSAIDs], conventional synthetic disease-modifying antirheumatic drugs [csDMARDs], and tumor necrosis factor inhibitors [TNFi]) was defined, with 6 possible transitions. Restricted mean sojourn times in each state were estimated. Then, predictors of those transitions were assessed by multivariable Cox models.Results: A total of 686/708 (96.9%) patients who had > 1 visit were analyzed. At cohort entry, 199 (29%) were untreated, 427 (62.2%) were receiving NSAIDs, 60 (8.7%) csDMARDs, and none were receiving TNFi. Over the follow-up period, patients mostly (46.4% of the time) received NSAIDs, followed by TNFi (24.4% of the time). The presence of sacroiliitis on radiographs, inflammatory bowel disease, and articular index were jointly associated with the transition to NSAIDs. Longer duration in the previous state often decreased the hazard of the transition to csDMARDs or TNFi. Worse disease activity outcomes increased the hazard of most transitions.Conclusion: To our knowledge, this was the first study using a multistate model to easily represent different treatment states, detailing the transitions across them and their associated factors. Different time profiles for the management of patients with axSpA were identified, including in those abstaining from treatment up to a significant proportion of patients treated with csDMARDs.
Although systemic treatments are warranted in aggressive forms of classic and endemic Kaposi sarcomas (KS), therapeutic guidelines are lacking for those nonimmunodeficient subtypes. In this retrospective multicentre study, we showed that paclitaxel, liposomal doxorubicin and low-dose interferon had good overall response rates for nonimmunodeficient KS with acceptable tolerance profiles. In addition, we highlighted the aggressiveness of endemic KS compared with classic KS with a higher risk of dissemination and response depletion as progression proceeded.
Severe COVID-19 is characterized by an aberrant immune response leading to systemic inflammation, organ dysfunction and high mortality among hospitalized patients. Mesenchymal stromal cells (MSCs), due to their immunomodulatory and tissue-reparative properties, are a potential therapeutic option. This study evaluated the safety of Wharton's Jelly-derived MSCs (WJ-MSCs) in patients with severe COVID-19 pneumonia. ProTrans19+ is a phase II, randomized, double-blind, placebo-controlled trial. Adults hospitalized with severe COVID-19 pneumonia (i.e., patients requiring either >4L/min of supplemental oxygen, and/or noninvasive ventilation and/or high-flow oxygen therapy to achieve arterial oxygen saturation >96%) were randomized 1:1 to receive a single intravenous infusion of 100 × 10⁶ WJ-MSCs (ProTransR) or placebo. The primary endpoint was a composite of death or requirement for invasive mechanical ventilation within 15 days after intervention. Secondary endpoints included changes in clinical status, time to improvement, hospital and ICU length of stay and safety outcomes. Bayesian and frequentist methods were used for statistical analysis. Between 2021 and 2023, 1519 COVID patients were screened, 46 were eligible and 19 subjects were randomized (WJ-MSC, n = 9; placebo, n = 10). Due to slow accrual and evolving pandemic dynamics, the trial was terminated early after enrolment of 19 participants. The infusion was well tolerated, with only grade 1 adverse events reported in both groups. One WJ-MSC recipient died, but the DSMB deemed the event unrelated to the intervention. The estimated primary event rate was 11% (95% CI: 0-48%) in the WJ-MSC arm and 0% (95% CI: 0-31%) in the placebo arm. The posterior probability of achieving a ≥20% absolute risk reduction in the primary event rate in favor of WJ-MSC was 0.7%. No significant differences were observed in secondary outcomes. The administration of WJ-MSCs was safe in multi-morbid patients with severe COVID-19 pneumonia receiving multiple concomitant therapies. The small sample size precludes efficacy conclusions. The study highlights the logistical and methodological challenges of conducting advanced therapy trials during a rapidly evolving pandemic and the need for context-sensitive designs.